Relationship between beta-cell mass and diabetes onset - PubMed (original) (raw)

Relationship between beta-cell mass and diabetes onset

A V Matveyenko et al. Diabetes Obes Metab. 2008 Nov.

Abstract

Regulation of blood glucose concentrations requires an adequate number of beta-cells that respond appropriately to blood glucose levels. beta-Cell mass cannot yet be measured in humans in vivo, necessitating autopsy studies, although both pre- and postmorbid changes may confound this approach. Autopsy studies report deficits in beta-cell mass ranging from 0 to 65% in type 2 diabetes (T2DM), and approximately 70-100% in type 1 diabetes (T1DM), and, when evaluated, increased beta-cell apoptosis in both T1DM and T2DM. A deficit of beta-cell mass of approximately 50% in animal studies leads to impaired insulin secretion (when evaluated directly in the portal vein) and induction of insulin resistance. We postulate three phases for diabetes progression. Phase 1: selective beta-cell cytotoxicity (autoimmune in T1DM, unknown in T2DM) leading to impaired beta-cell function and gradual loss of beta-cell mass through apoptosis. Phase 2: decompensation of glucose control when the pattern of portal vein insulin secretion is sufficiently impaired to cause hepatic insulin resistance. Phase 3: adverse consequences of glucose toxicity accelerate beta-cell dysfunction and insulin resistance. The relative contribution of beta-cell loss versus beta-cell dysfunction to diabetes onset remains an area of controversy. However, because cytotoxicity sufficient to induce beta-cell apoptosis predictably disturbs beta-cell function, it is naive to attempt to distinguish the relative contributions of these linked processes to diabetes onset.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest:

The authors declare no conflict of interest.

Figures

Fig. 1

Fig. 1

Blood glucose values over the years prior to diabetes onset in prospective study. Glucose effects model. Copyright ©2007 American Diabetes Association. From Ref. [37]. Reprinted with permission from The American Diabetes Association.

Fig. 2

Fig. 2

Fractional β-cell volume in obese humans [non-diabetic (ND), impaired fasting glucose (IFG) and type 2 diabetes (T2DM)]. Copyright © 2003 American Diabetes Association. From Ref. [4]. Reprinted with permission from American Diabetes Association.

Fig. 3

Fig. 3

Fasting glucose and arterial insulin concentrations in sham-operated dogs and in dogs that underwent 50% pancreatectomy (DPx) (top panels). Corresponding deconvolved insulin secretion rate and insulin clearance rate (middle panels), Nand corresponding representative profiles of portal vein insulin concentrations (lower panels) in sham and 50% pancreatectomized dogs (DPx). Copyright © 2003 American Diabetes Association. From Ref. [62]. Reprinted with permission from The American Diabetes Association.

Similar articles

Cited by

References

    1. Meier JJ, Butler PC. Insulin secretion. In: DeGroot LJJJ, editor. Endocrinology. 5 edn. Philadelphia: Elsevier Saunders; 2005. pp. 961–973.
    1. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667–687. - PubMed
    1. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res. 1985;4:110–125. - PubMed
    1. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110. - PubMed
    1. Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab. 2003;88:2300–2308. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources